[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100612925":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":18,"centralContacts":19,"locations":29,"responsibleParty":53,"collaborators":18,"id":55,"slug":18,"hasResults":56,"nctId":57,"briefTitle":58,"officialTitle":58,"acronym":59,"eligibilityCriteria":60,"healthyVolunteers":56,"sex":61,"minAge":62,"maxAge":18,"enrollmentInfo":63,"targetDuration":18,"studyType":66,"phases":67,"briefSummary":69,"conditions":70,"keywords":72,"overallStatus":76,"whyStopped":18,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":86},{"fullName":5,"class":6},"Centre Henri Becquerel","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Multimodal approach","EXPERIMENTAL","The patient will undergo multimodal imaging and biological sampling",[13],"Other: Multimodal approach",[15],{"type":6,"name":9,"description":16,"armGroupLabels":17,"otherNames":18},"The patient will undergo MRI, PET\u002Fcan and biological samples",[9],null,[20,25],{"name":21,"role":22,"phone":23,"phoneExt":18,"email":24},"Lise-Marie Roussel, MD","CONTACT","+33276015781","lise-marie.roussel@chb.unicancer.fr",{"name":26,"role":22,"phone":27,"phoneExt":18,"email":28},"Doriane Richard, PhD","+33232082985","doriane.richard@chb.unicancer.fr",[30,43],{"facility":5,"status":18,"city":31,"state":18,"zip":18,"country":32,"countryCode":33,"cosmosGeoPoint":34,"geoPoint":39,"contacts":40},"Rouen","France","FR",{"type":35,"coordinates":36},"Point",[37,38],1.09932,49.44313,{"lat":38,"lon":37},[41],{"name":42,"role":22,"phone":23,"phoneExt":18,"email":24},"Lise-Marie Roussel, Md",{"facility":44,"status":18,"city":31,"state":18,"zip":18,"country":32,"countryCode":33,"cosmosGeoPoint":45,"geoPoint":47,"contacts":48},"Centre Hospitalier Universitaire",{"type":35,"coordinates":46},[37,38],{"lat":38,"lon":37},[49],{"name":50,"role":22,"phone":51,"phoneExt":18,"email":52},"Sophie Deneuve","+33232888990","sophie.deneuve@chb.unicancer.fr",{"type":54,"investigatorFullName":18,"investigatorTitle":18,"investigatorAffiliation":18,"oldNameTitle":18,"oldOrganization":18},"SPONSOR","100612925",false,"NCT07259915","Multimodal Prediction of Response to Chemoradiotherapy for Squamous Cell Carcinoma of the Head and Neck","MULTINECK","Inclusion Criteria:\n\n* Patient with squamous cell carcinoma of the oropharynx (cT2-cT4) or squamous cell carcinoma of the oral cavity (cT2-cT4)\n* With lymph node involvement (cN1, cN2, or cN3) (confirmation of lymph node involvement after review of imaging in CCP and without histological confirmation required)\n* Eligible for curative treatment with cisplatin-based chemoradiotherapy alone (100 mg\u002Fm2 every 3 weeks or 40 mg\u002Fm2 weekly)\n* Regardless of p16 status\n* Affiliated with or covered by a social security system\n\nExclusion Criteria:\n\n* Head and neck squamous cell carcinomas in other locations (salivary gland, larynx, hypopharynx, cavum, sinuses)\n* Primary squamous cell carcinoma of the lymph nodes\n* History of radiotherapy to the head and neck region\n* Radiochemotherapy not based on the use of cisplatin\n* Pregnant or breastfeeding women\n* History of invasive cancer in the last 3 years (except for Breslow melanoma less than 1 mm)\n* Contraindication to MRI, CT, or PET\u002FCT\n* Allergy or contraindication to iodine, gadolinium, or 18F-FDG\n* Uncontrolled diabetes (fasting blood glucose greater than 12 mmol\u002Fl)\n* Patients unable to understand the study for any reason or to comply with the trial requirements (language, psychological, geographical issues, etc.)\n* Patients under guardianship or conservatorship\n* Patients deprived of their liberty by judicial or administrative decision\n* Patients undergoing psychiatric care that renders them incapable of giving their consent\n* Patients admitted to a health or social care facility for purposes other than research","ALL","18 Years",{"count":64,"type":65},152,"ESTIMATED","INTERVENTIONAL",[68],"NA","The goal of the study lies in offering a multimodal analysis of the post-therapeutic response based on both quantitative parameters and radiomics (CT, MRI, and PET imaging), and on tumor biology, in particular the hypersensitive detection of tumor DNA.",[71],"Squamous Cell Cancer of Head and Neck (SCCHN)",[73,74,75],"multimodal approach","CT DNA","Resonance Magnetic Imaging","NOT_YET_RECRUITING","2025-11-21",{"date":79,"type":80},"2025-12-02","ACTUAL",{"date":82,"type":65},"2025-12-01",{"date":84,"type":65},"2030-08-01",{"name":5,"class":6},2]